Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants - Wikidata - awgldk - TriplyDB

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants

http://www.wikidata.org/entity/Q35595661

about

Study protocol: Insight 46 - a neuroscience sub-study of the MRC National Survey of Health and Development.Communicating mild cognitive impairment diagnoses with and without amyloid imaging.Amnestic MCI Patients' Perspectives toward Disclosure of Amyloid PET Results in a Research Context.Suicide and assisted dying in dementia: what we know and what we need to know. A narrative literature review.Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design Recruiting to preclinical Alzheimer's disease clinical trials through registries.Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.Attitudes toward clinical trials across the Alzheimer's disease spectrum Study partners should be required in preclinical Alzheimer's disease trials.Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia.Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.Safety of disclosing amyloid status in cognitively normal older adults.Perspectives on Communicating Biomarker-Based Assessments of Alzheimer's Disease to Cognitively Healthy Individuals.From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting.Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review

P2860

Q33576727-93E2F356-3620-48DA-B6D1-13DD5E8D6115 Q33640373-7CFCD42E-1B80-4ECE-A91C-F03B70F5ACB5 Q33840562-F6C0DB3D-7BC4-4592-B2E3-39B76507AC82 Q36360331-D4460EE0-0477-424C-AE92-BAABF9C4B5D8 Q36638757-1F3B828B-A0D9-471D-927F-F97AD5CDC027 Q36719734-B4F2B163-8DEC-4041-A219-9EF139F52377 Q36883137-8488BE8F-40A3-4A73-8A18-AB933CFB476C Q36885357-B0DAB339-F17E-4285-A0D9-B3539A5D8AF1 Q37654117-5A3DDF81-771D-46F9-9941-6369B74E9C37 Q38821788-62F4FB3D-A6AB-4DEF-888B-80AAC624325A Q38903262-C8736A02-8F1E-460D-9D9F-59B5991B3896 Q42278977-612815B1-F3A2-46E5-B7D1-CF55CF8CD73C Q46028917-1AB0F5CC-1DE9-4A0D-AFB5-E8A1EE77294C Q46427093-4B2447E8-3012-47EA-87B4-D6FA5D2A9121 Q47742387-1014D5EC-8967-489C-8EEF-0F16CD71B30B Q47953945-C1A7BCDE-8844-471D-8A4A-3DD5DE1489BC Q50421914-9FA2E5B8-7AD8-4113-ABCE-867AD44C4D57 Q55434541-7BC2238C-5ADF-41ED-BD15-207D77C51E8D Q56373543-F4103B2D-8CB4-401C-80A1-6C7CB76A4AA2 Q57174282-6AAADA52-8DD1-4B73-81A4-8037428CF9CD

P2860

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants

http://www.wikidata.org/entity/Q35595661

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Development of a process to di ...... er adult research participants

@ast

Development of a process to di ...... er adult research participants

@en

type

label

Development of a process to di ...... er adult research participants

@ast

Development of a process to di ...... er adult research participants

@en

prefLabel

Development of a process to di ...... er adult research participants

@ast

Development of a process to di ...... er adult research participants

@en

P1433

Q35595661-90ADABEB-9257-42F3-9239-069743B145F3

P1476

Q35595661-F782BE77-4FCA-4EBD-8012-BCF05F20E907

P2093

Q35595661-1100F2DA-D403-4F65-9658-457DB711056C

Q35595661-1A4529E2-0F4C-4FB5-AE6D-C7380CFBCDC3

Q35595661-55AA4621-4AB4-4FCB-B91D-DD25E1368202

Q35595661-5EC75957-F34E-4553-92F0-4E53120DECC4

Q35595661-D82E05CF-5E71-4A23-A6B1-9A73C6205E61

P2860

Q35595661-0B7DD9F1-3256-4BED-BA23-B8A84D90EFD9

Q35595661-185DA5CC-D87D-4A33-ABD1-7F65E30BC9DD

Q35595661-2BE089D8-2556-4EF4-A606-DE042B9D30E4

Q35595661-2CB0C9C6-B7D3-4273-835C-82D3A7524BF2

Q35595661-353C31CB-9C8A-461E-A4CC-498B4572318E

Q35595661-39B8315B-D06A-43B9-821C-72B3BA17F4F2

Q35595661-3EB8A884-9234-4E10-B279-560E1C54D8E4

Q35595661-4016695E-903A-408A-B1F9-9377FA24177E

Q35595661-4AE79854-88ED-4813-A256-97E5A492F189

Q35595661-4CDB5F0C-3983-47A4-BC63-5465BBC740D1

P2888

Q35595661-7771AD71-51CF-4E43-924B-938282FA1AE4

P304

Q35595661-6D0D6F61-9CAF-4DF1-B8B4-92275F8158CD

P31

Q35595661-8F09BC7E-B2BD-4F50-9FAF-AEBBA1A69175

P356

Q35595661-D7228DA3-3179-4D3E-90A6-06E2F02F87DA

P407

Q35595661-9D5D29C2-2B18-4FCE-89DA-6CBE716B01F9

P433

Q35595661-B3DEE146-AB58-4151-B30F-E87B19DB081A

P478

Q35595661-DCF144EA-042A-409F-8CF3-77C5AB037EC3

P50

Q35595661-47CD587E-311E-4EFE-9ECF-E7A0A1DE5127

Q35595661-69B14994-6672-4638-B9A8-A95CC2254D79

Q35595661-E3244F13-D1FE-442B-A91C-8801A795AD81

P577

Q35595661-EF78A7A4-98C7-4AA0-A908-EA0A65D3C1A2

P5875

Q35595661-C0560E06-0A36-4637-BB0C-9E2DBD532B12

P6179

Q35595661-A83F5BBD-62D5-47BF-8E3B-E176CE069040

P698

Q35595661-A6B403D0-4153-4907-8073-A5FC4FD728C2

P921

Q35595661-791A64A9-C0E8-4DDA-8A13-F843A2DCC91D

P932

Q35595661-41B11AC5-2F65-4192-90F3-FE81B7BF3EBE

P356

S13195-015-0112-7

P1433

Alzheimers Research & Therapy

P1476

Development of a process to di ...... er adult research participants

@en

P2093

Joshua D Grill

http://www.w3.org/2001/XMLSchema#string

Keith A Johnson

http://www.w3.org/2001/XMLSchema#string

Kristin Harkins

http://www.w3.org/2001/XMLSchema#string

Megan Healy

http://www.w3.org/2001/XMLSchema#string

Pamela Sankar

http://www.w3.org/2001/XMLSchema#string

P2860

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults

The A4 study: stopping AD before symptoms begin?

The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI).

Should we disclose amyloid imaging results to cognitively normal individuals?

Where there is no evidence: use of expert consensus methods to fill the evidence gap in low-income countries and cultural minorities.

Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics

Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.

Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease

P2888

s13195-015-0112-7

P304

26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13195-015-0112-7

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Jason Karlawish

Robert C. Green

P577

2015-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281407596

http://www.w3.org/2001/XMLSchema#string

P6179

1017835648

http://www.w3.org/2001/XMLSchema#string

P698

25969699

http://www.w3.org/2001/XMLSchema#string

P921

amyloid imaging

P932

4428104

http://www.w3.org/2001/XMLSchema#string